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Context: Polymorphisms in genes involved in regulation, biosynthesis, metabolism, and actions of
testicular sex hormones may influence hormone balance and phenotype of aging men.
Objective:Weinvestigated the relationshipsbetweenpolymorphisms ingenes related topituitary-
testicular endocrine function and health status.
Design and Setting:Using cross-sectional baseline data,we conducted amultinational prospective
cohort observational study consisting of a population survey of community-dwelling men.
Participants:A total of 2748men, aged 40–79 (mean SD, 60.2 11.2) yr, were randomly recruited
from eight European centers. Forty-three polymorphismswere genotyped in the following genes:
androgen receptor (AR), estrogen receptor- and - (ESR1 and ESR2), steroid 5-reductase type II
(SRD5A2), 17-hydroxylase/17,20-lyase (CYP17A1), aromatase (CYP19A1), sex hormone-binding
globulin (SHBG), LH -subunit (LHB), and LH receptor (LHCGR).
Main Outcome Measures: We measured the associations between gene polymorphisms and en-
docrine, metabolic, and phenotypic parameters related to aging and sex hormone action.
Results: Several polymorphisms in SHBG,ESR2,AR,CYP19A1, and LHBwere significantly associated
with circulating levels of SHBG, LH, total, free, and bioavailable testosterone and estradiol, the
LH testosteroneproduct, and indicesof insulin sensitivity.Apart fromseveralpreviously reported
associations between genes affecting estrogen levels and heel ultrasound parameters, no associ-
ations existed between polymorphisms and nonhormonal variables (anthropometry, blood lipids,
blood pressure, hemoglobin, prostate symptoms, prostate-specific antigen, sexual dysfunction,
cognition).
Conclusion: In aging men, polymorphisms in genes related to the pituitary-testicular endocrine
function significantly influence circulating LH, testosterone, and estradiol levels, but the down-
stream effects may be too small to influence secondary phenotypic parameters. (J Clin Endocrinol
Metab 95: 1898–1908, 2010)
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CYP17A1, 17-hydroxylase/17,20-lyase; CYP19A1, aromatase; E2, estradiol; ESR1 and
ESR2, estrogen receptor- and -; HDL, high-density lipoprotein; HOMA-B, homeostasis
model assessment for pancreatic -cell function; HOMA-IR, homeostasis model assess-
ment for insulin resistance; HOMA-S, homeostasis model assessment for sensitivity; indel,
insertion/deletion; IPSS, International Prostate Symptom Score; LD, linkage disequilibrium;
LHB, LH -subunit; LHCGR, LH receptor; MAF, minor allele frequency; PSA, prostate-
specific antigen; QUICKI, quantitative insulin sensitivity check index; SHBG, sex hormone-
binding globulin; SNP, single nucleotide polymorphism; SRD5A2, steroid 5-reductase
type II; T, testosterone; UTR, untranslated region; V, variant; WT, wild-type.
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The aging of men is affected by gender-specific environ-mental and lifestyle factors, such as obesity, physical
activity, smoking, and alcohol consumption (1–3). How-
ever, the most conspicuous gender differences are the life-
long exposure of men to testicular androgens and of
women to ovarian estrogens. Unlike women, men have a
lifelong exposure to androgens and do not experience a
sudden cessation of gonadal function comparable to
menopause. Cross-sectional and longitudinal population
studies demonstrate that although most hormones with
anabolic actions (e.g. GH, IGF-I, and dehydroepiandros-
terone) decrease in healthy men progressively with aging,
the decline of testicular testosterone (T) production is
gradual, with large interindividual variability (1, 3). The
average decline of serum total T between ages 20 and 80
yr is 35%, and the concomitant decline of the biologically
active free fraction of T is 50%; moreover, the reference
range is large in serum gonadotropins (1–10 IU/liter) and
T [2.9–8.6g/liter (10–30 nmol/liter)]. The aging-related
decline in T levels is mainly due to primary Leydig cell
failure but can also be combined with a decline of gonad-
otropin secretion associated with obesity and comorbidi-
ties (3). However, the prevalence of late-onset hypogo-
nadism, defined as the decline of T levels with associated
symptoms, remainsunknown; apparently, only aminority
of men become truly hypogonadal with aging (1–3).
Multiple hereditary (polymorphisms, race), lifestyle,
environmental (obesity, diet, stress), socioeconomic (ed-
ucation, income, living conditions), somatic, psychologi-
cal, and health (including drugs) factors contribute to the
large interindividual variability of the basal activity and
age-related decline of the pituitary-gonadal function in
men (3, 4). Limited information is currently available on
polymorphisms in genes affecting the regulation, produc-
tion, actions, andmetabolisms of androgens (5, 6). There-
fore, in the present study, we genotyped selected polymor-
phisms in nine genes [AR (androgen receptor), ESR1 and
ESR2 (estrogen receptor- and -), SRD5A2 (steroid 5-
reductase type II), CYP17A1 (17-hydroxylase/17,20-
lyase), CYP19A1 (aromatase), sex hormone-binding
globulin (SHBG),LHB (LH-subunit), andLHCGR (LH
receptor)] shown previously to have phenotypic effects
and related them to the production or action of andro-
gens and estrogens in a cohort of middle-aged and el-
derly Europeanmen. Their associationswith circulating
levels of selected hormones, alterations upon aging, and
phenotypic effects were assessed.
Subjects and Methods
Subjects
Subjects included in the analyses are participants in the Eu-
ropean Male Aging Study (EMAS), a multicenter population-
based study of the determinants of male aging. A total of 3369
community-dwelling men aged 40–79 yr were recruited from
eight European centers: Florence (Italy), Leuven (Belgium), Lodz
(Poland), Malmo¨ (Sweden), Manchester (UK), Santiago de Com-
postela (Spain), Szeged (Hungary), andTartu (Estonia). Ethical ap-
provalwas obtained at each center, andparticipants gave informed
consent. Further details on the study design andmethodology used
inEMAScanbe found inRef. 7. The ethnic backgroundof themen
was almost exclusively European (with the exception that at least
one parent or grandparent of 21 men was born outside Europe).
Blood sampling and processing
A single sample of morning fasting venous blood (taken be-
fore 1000 h) was processed and stored according to standard
protocols and used for hormone, hematological, and biochem-
ical measurements, as well as for DNA extraction using the phe-
nol:chloroform method. A total of 2981 subjects consented to
extraction and genetic analysis of their DNA.
Genetic analysis
Celera and dbSNP single nucleotide polymorphism (SNP)
databases were searched for SNPs with a minor allele fre-
quency (MAF) of at least 5% for AR, CYP17A1, CYP19A1,
ESR1, ESR2, LHB, LHCGR, SHBG, and SRD5A2. Most of
the SNPs and other polymorphisms in these genes selected for
genotyping have previously been shown to influence the bal-
ance of male pituitary-testicular hormones (5, 6). This re-
sulted in a total of 39 SNPs, two repeats (TA repeat in
SRD5A2 and TAAAA repeat in SHBG), one insertion/dele-
tion (indel) (TCT in CYP19A1), and a variant (V) in LHB
being genotyped (Table 1).
SNPs were genotypedwithMALDI (matrix-assisted laser de-
sorption/ionization)-TOF (time-of-flight)mass spectrometry us-
ing SequenomMassARRAY technology following themanufac-
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turer’s instructions (www.sequenom.com). Genotyping of the
SHBG repeat, SRD5A2 repeat, and the CYP19A1 indel was
described previously (8). Genotyping of V-LHB was based on
differential immunoreactivity of wild-type (WT) and V forms of
LH in serum samples, as described before (9). One of the assays
detects both WT- and V-LH, the other only WT hormone. The
ratio of assays WT/WTV correlates with the LHB genotype
(1 WT/WT, 0.5 WT/V, 0 V/V).
Quality control thresholds for samples and assays were set to
90%.Polymorphismswere tested fordeviation fromHardy-Wein-
berg equilibrium in the population and excluded if P  0.01.
Allele frequencies were also compared with HapMap data or
the literature, where possible, to check for consistency.
Linkage disequilibrium (LD; i.e. nonrandom association of
alleles) was assessed for each gene. The LD between SNPs was
determined by pairwise comparisons of r2 (correlation coeffi-
cient between SNPs; if r2 1, SNPs predict one another) and D
(likelihood that recombination has occurred between SNPs; if
D  1, no recombination has occurred) using Haploview
(Broad Institute, Cambridge, MA) version 3.32 (10). LD be-
tween SNPs and multiallelic markers was determined using
Helixtree (Statistics.com, Bozeman, MT).
TABLE 1. Polymorphisms genotyped in the genes related to pituitary-testicular endocrine function
Gene Position Marker ID Location in gene Base change MAF
AR Xq11.2-q12 rs6152 Exon 1 G3A 0.17
rs1204038 Intron 1 C3T 0.16
rs2255702 Intron 1 C3T 0.15
rs7061037 Intron 1 A3G 0.15
rs5918760 Intron 1 C3T 0.16
CYP17A1 10q24.3 rs743572 5 UTR A3G 0.41
rs743575 Intron 2 A3C 0.30
CYP19A1 15q21.1 rs2446405 5 UTR T3A 0.17
rs2445765 5 UTR G3C 0.17
rs1870049 5 UTR T3C 0.11
rs2470144 5 UTR A3G 0.46
rs730154 Intron 1 A3G 0.15
rs936306 Intron 1 C3T 0.15
rs749292 Intron 1 G3A 0.45
rs12050767 Intron 1 T3C 0.46
rs10519299 Intron 1 C3G 0.46
rs727479 Intron 2 T3G 0.32
rs2414096 Intron 2 A3G 0.49
rs11575899 Intron 4 (TCT indel) TCT3 0.34
rs10046 3 UTR T3C 0.47
rs4646 3 UTR G3T 0.25
ESR1 6q25.1 rs488133 5 UTR C3T 0.32
rs2077647 Exon 1 (SerSer) A3G 0.49
rs1801132 Exon 4 (ProPro) C3G 0.22
rs726282 Intron 4 C3A 0.10
ESR2 14q23.2 rs1256031 Intron3 T3C 0.46
rs1256049 Exon 6 (ValVal) G3A 0.04
rs1256063 Intron7 C3T 0.07
LHB 19q13.32 rs2013040 3 UTR C3T 0.04
Variant Exonic (Trp8Arg/Ile15Thr) T3C/ T3C 0.08
LHCGR 2p21 rs4555391 Intron 1 T3G 0.48
rs10495959 Intron 1 T3C 0.07
rs7562693 Intron 3 T3C 0.46
rs6545061 Intron 4 C3T 0.49
rs12713013 Intron 7 C3T 0.07
SHBG 17p13-p12 TAAAA repeat Promoter 6 Repeats 0.29
7 Repeats 0.06
8 Repeats 0.34
9 Repeats 0.22
10 Repeats 0.08
11 Repeats 0.01
12 Repeats 0.01
rs1799941 Intron 1 G3A 0.27
rs6259 Exon 8 (AspAsn) G3A 0.10
SRD5A2 2p23 rs632148 5 UTR G3C 0.32
rs523349 Exon 1 (LeuVal) C3G 0.30
rs765138 Intron 2 C3A 0.41
rs7571644 Intron 3 A3G 0.12
TA repeat Exon 5 0 Repeats 0.90
9 Repeats 0.10
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Hormone assays
Each serum sample was assayed for T, estradiol (E2), LH,
FSH, and SHBG. LH, FSH, and SHBG were measured as de-
scribed previously (3, 7). T and E2 were measured using gas
chromatography-mass spectrometry as described before (11,
12). The lower limit of quantification of T was 170 pmol/liter,
and of E2, 2.2 pmol /liter. The intra- and interassay coefficients
of variation in T measurements were 2.9 and 3.4%, and in E2
measurements, 6.4 and 10.1%, respectively. Free and bioavail-
able (non-SHBG-bound) T and E2 levels were derived using the
total hormone measurement, and levels of SHBG and albumin
using mass action equations and association constants (13, 14).
LH  T product was calculated by multiplying LH and total T
levels and E2/T ratio from total T and total E2 levels.
Measures of health status
Height,weight, bodymass index (BMI),waist circumference,
and waist-hip ratio were assessed as previously described (7).
Skinfold thicknesses and body circumferences were used to cal-
culate the percentage of body fat (15). Routine hematological
and biochemical markers were measured using standardized
methods under good laboratory practice conditions in interna-
tionally and/or nationally accredited hospital laboratories in
each center (7). Hematology analyses included hemoglobin,
platelet, and red and white cell counts. Biochemical measure-
ments included glucose, albumin, cholesterol, high-density
lipoprotein (HDL) cholesterol, triglycerides, and low-density li-
poprotein cholesterol [calculated from total and HDL choles-
terol, and fasting triglycerides using the Friedewald equation
(16)]. Insulin levelsweremeasured at a single laboratoryusing an
ELISA assay (17). The homeostasis model assessment was used
to estimate insulin resistance (HOMA-IR), sensitivity (HOMA-
S), and pancreatic -cell function (HOMA-B) (18). The quanti-
tative insulin sensitivity check index (QUICKI) was calculated
(19). Prostatic symptoms were assessed using the International
Prostate SymptomScore (IPSS) questionnaire (20) and the risk of
prostatic cancer by measuring serum prostate-specific antigen
(PSA). Sexual and cognitive functionswere assessed as described
before (7).
Statistical analyses
In the analysis hormone levels, hematology, biochemistry,
lipids, measures of insulin sensitivity, PSA/IPSS levels, and cog-
nitive tests were treated as continuous variables. Measures of
sexual dysfunctionwere dichotomized. Erectile dysfunctionwas
defined as the inability to reach and keep an erection good
enough for sexual intercourse in the last 4 wk (never/sometimes
vs. usually/always) (21). Poor morning erection was defined as
the frequency ofmorning erections in the last 4wk (none/1 per
month vs. 2–3 per month or more), and poor libido was defined
as loss of interest in sex in the last 4 wk (completely/much less
interested vs. less interested/no change). Because the six repeats
allele of the SHBG TAAAA repeat reportedly reduces transcrip-
tional activity (22), this polymorphism was dichotomized into
six repeats allele vs. at least seven repeats allele. Only two alleles
were present for the SRD5A2 TA repeat, zero repeats and nine
repeats, so it was dichotomized into zero repeats allele vs. nine
repeats allele.
Linear regression was used to test for association between
each of the endocrine factors and genotypes for each polymor-
phism. The difference inmean levels of each hormone and SHBG
was estimated for subjects with one copy of the minor allele and
subjects with two copies of the minor allele compared with sub-
jectswith zero copies. Results are adjusted for age and center and
reported as the adjustedmean values of the endocrine factors for
a subject ofmean age (60 yr) living in center 1 (Florence). Results
are also reported as differences (-coefficients) and 95% confi-
dence intervals (CI). The SE values were corrected to account for
differences between centers. To reduce the chance of false-pos-
itive findings, only associations with P  0.01 were prioritized
for further analysis. Polymorphisms associated with endocrine
factorswere subsequently tested forassociationwithmeasuresof
health status: anthropometry, hematology, biochemistry and
lipidmeasures, insulinaction, and sexual, prostate, andcognitive
function. Because the measures of sexual dysfunction were di-
chotomous variables, logistic regression was used, with results
reported as odds ratios and 95%CI. Interactions between genes
found to be associated with hormone levels were assessed by
fitting interaction terms between the relevant SNPs. To further
explore the impact of center, interaction terms were fitted be-
tween polymorphism and center to determine whether the asso-
ciation observed differed across centers. Statistical analysis was
performed using STATA version 9.2 (http://www.stata.com).
Results
The study population
Of the 2981 DNA samples of the EMAS cohort geno-
typed, 233 were excluded from the analysis due to failing
sample quality control. The analysis was conducted on
the remaining 2748 subjects. The SNP and repeat poly-
morphisms detected in the AR, CYP17A1, CYP19A1,
ESR1, ESR2, LHB, LHCGR, SHBG, and SRD5A2
genes are presented in Table 1. All SNPs were in Hardy-
Weinberg equilibrium (P  0.01). Subject characteris-
tics have been partly published before (7, 8, 23) and are
presented in Supplemental Table 1, published on The
Endocrine Society’s Journals Online web site at http://
jcem.endojournals.org.
Influence of SHBG polymorphisms
We genotyped three SHBG polymorphisms, a TAAAA
repeat polymorphism in the promoter region, a G 3 A
polymorphism (rs1799941) in intron 1, and a nonsyn-
onymous G 3 A polymorphism (rs6259) in exon 8
(Asp356Asn). None of these SNPs were associated with
age. The repeat polymorphismwas associated with serum
levels of SHBG, total E2, total T, and the LH T product
(Table 2); in each case, shorter repeats were associated
with higher levels of these hormonal parameters, and the
effects were greater in variant homozygotes than het-
erozygotes. The A allele of the intron 1 polymorphism
(rs1799941) was highly significantly associated with
higher serum SHBG, total E2, total T, and LH  T prod-
uct. The association with higher serum LH was less
marked, with only the variant homozygotes reaching
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statistical significance. The findings with the two poly-
morphisms were similar, owing to the high level of LD
between them (r2  0.89). The minor A allele of the
exon 8 SNP (rs6259) was associated with higher free T,
but it only reached significancewhen comparing variant
heterozygotes (GA) to commonhomozygotes (GG). The
association between the polymorphism in intron 1
(rs1799941) and LH T product significantly differed
across centers (P  0.048). Florence, Santiago, and
Tartu showed a significantly different effect in het-
erozygotes compared with the other five centers. This
was the only significant difference detected between the
centers.
No associations (i.e. P  0.01) were observed be-
tween SHBG polymorphisms and nonhormonal pheno-
types including anthropometric parameters (height,
weight, BMI, waist circumference, waist-hip ratio, per-
centage body fat), hematology (hemoglobin, platelets,
blood pressure), laboratory parameters of metabolic
function (total, low-density lipoprotein- and HDL-cho-
lesterol, triglycerides, IPSS), PSA, measures of insulin sen-
sitivity/resistance (HOMA-IR, HOMA-B, HOMA-S,
QUICKI), sexual function (erectile dysfunction, morning
erection, loss of libido), or with cognitive outcomes (re-
sults not shown).
Influence of AR, ESR1, and ESR2 polymorphisms
In our previous report, the common AR CAG repeat
polymorphism in exon 1 showed significant association
with higher circulating T and E2 in the current study pop-
ulation (23). We now assessed the associations of a G3
A SNP (rs6152) in exon 1 and four SNPs (Table 1) in
intron 1 ofAR. Because of a very strong LD (r2 0.97) for
all pair-wise comparisons, we only present the data on the
rs6152 polymorphism (the findings with the others were
very similar). There was no association with age. The mi-
nor allele of the polymorphism was significantly associ-
ated with lower serum total E2, free E2, and bioavailable
E2 (Table 3).
Four and three SNPs were genotyped for the two
estrogen receptor genes, ESR1 and ESR2, respectively
(Table 1). There was no association between these SNPs
and age. One ESR2 SNP (rs1256031) showed signifi-
cant association with lower E2/T ratio, but only when
comparing variant homozygotes to common homozy-
gotes (Table 3). The results did not significantly differ
TABLE 2. Influence of SHBG polymorphisms on sex hormones
Sex hormone Polymorphism Genotype n (%) Mean valuesa (95% CI) P value
SHBG (nmol/liter) rs1799941b GG 1466 (53.6) 37.94 (36.06, 39.82)
GA 1066 (39.0) 42.88 (40.90, 44.86) 1.17  1012
AA 203 (7.4) 50.18 (47.27, 53.09) 5.17  1021
TAAAA 7/7 1360 (50.7) 38.09 (36.20, 39.98)
6/7 1097 (40.9) 42.24 (40.27, 44.20) 3.74  1019
6/6 225 (8.4) 49.12 (46.29, 51.95) 1.64  1018
LH (IU/liter) rs1799941 GG 1466 (53.6) 6.10 (5.68, 6.52)
GA 1066 (39.0) 6.19 (5.75, 6.64) 5.41  101
AA 203 (7.4) 6.93 (6.27, 7.59) 5.25  103
Total E2 (pmol/liter) rs1799941 GG 1466 (53.6) 69.64 (67.03, 72.25)
GA 1066 (39.0) 72.58 (69.83, 75.33) 2.69  103
AA 203 (7.4) 77.30 (73.20, 81.41) 3.35  105
TAAAA 7/7 1360 (50.7) 69.89 (67.26, 72.52)
6/7 1097 (40.9) 72.63 (69.89, 75.37) 5.70  103
6/6 225 (8.4) 76.18 (72.18, 80.17) 4.19  104
Total T (nmol/liter) rs1799941 GG 1466 (53.6) 15.92 (15.35, 16.50)
GA 1066 (39.0) 16.95 (16.34, 17.55) 5.81  106
AA 203 (7.4) 18.58 (17.65, 19.51) 4.19  1010
TAAAA 7/7 1360 (50.7) 16.00 (15.42, 16.58)
6/7 1097 (40.9) 16.90 (16.29, 17.50) 8.69  105
6/6 225 (8.4) 18.17 (17.26, 19.07) 1.23  107
Free T (pmol/liter) rs6259 GG 2214 (81.8) 297.18 (289.37, 305.00)
GA 460 (17.0) 307.73 (298.04, 317.41) 6.98  103
AA 32 (1.2) 310.20 (282.75, 337.64) 3.40  101
LH  T rs1799941 GG 1466 (53.6) 100.93 (92.44, 109.42)
GA 1066 (39.0) 108.03 (99.16, 116.91) 1.48  102
AA 203 (7.4) 133.08 (120.30, 145.86) 6.66  109
TAAAA 7/7 1360 (50.7) 101.00 (92.50, 109.50)
6/7 1097 (40.9) 107.92 (99.11, 116.74) 1.95  102
6/6 225 (8.4) 127.44 (115.06, 139.82) 6.77  107
a Adjusted mean value for a man aged 60 from center 1 (Florence).
b LD between rs1799941 and TAAAA repeat is high (r2  0.89), hence the large similarity in findings.
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between the centers. No associations (i.e. P  0.01)
were observed with the nonhormonal parameters.
Influence of LHB and LHCGR polymorphisms
Two LHB polymorphisms were determined, a 3-un-
translated region (UTR) C3 T SNP (rs2013040), and an
exon 2 Trp8Arg/Ile15Thr polymorphism, also defined as
V-LH (9, 24). There were no associations with age. The
former SNP showed significant association with higher
serum levels of free E2, bioavailable E2, and E2/T ratio
(Table 3). However, due to its rarity (MAF 0.04), these
results must be cautiously interpreted. The MAF of the
V-LHB allele in the different European centers ranged
from 7.34% in Szeged to 11.8% in Tartu (P  0.05), in
agreementwithapreviouslydocumentednorth-southgra-
dient in its frequency (9). The V allele was significantly
associated with lower LH levels (Table 3).
The LHCGR SNP (rs654061), present in intron 4 (Ta-
ble 1), was associated with lowered E2/T ratio but with
significance only in variant homozygotes (Table 3). No
associations (i.e. P 0.01) were observed with any of the
other nonhormonal phenotypes, neither were there dif-
ferences between centers (except for V-LHB; see above).
Influence of CYP17A1 and SRD5A2 polymorphisms
Neither of the two CYP17A1 polymorphisms deter-
mined (Table 1) showed significant associations with age,
hormones, or the nonhormonal parameters determined.
Five polymorphisms of the SRD5A2 gene were geno-
typed, four of them SNPs in the 5-UTR, exon 1 and in-
trons 2 and 3, and one being a TA repeat in exon 5 (Table
1). Of these, the intron 3 A 3 G SNP (rs7571644) was
associated with higher bioavailable T only in homozy-
gotes [mean bioavailable T level  8.27 nmol/liter; 95%
CI, 7.60, 8.93 for GG genotype (n  31, 1.1%) vs. 7.33
nmol/liter; 95% CI, 7.13, 7.53 for AA genotype (n 
2113, 66.3%); P  5.00  103]. Likewise, long TA re-
peats of exon 5 (9/9 vs. 0/0) were associated with higher
bioavailable T, but only in homozygotes [mean bioavail-
able T level 8.22 nmol/liter; 95%CI, 7.55, 8.90 for 9/9
genotype (n  30, 1.1%) vs. 7.32 nmol/liter; 95% CI,
7.12, 7.51 for 0/0 (n  2187, 80.5%) genotype; P 
8.01 103]. These associations did not differ by center.
No associations were observedwith the nonhormonal pa-
rameters including PSA and IPSS.
Influence of CYP19A1 polymorphisms
A total of 14 polymorphisms, located in the 5-UTR,
introns 1, 2, and 4, and in the 3-UTR of CYP19A1, were
genotyped (Table 1). No associations with age were ob-
served. Several associations were observed with serum
hormone levels (Table 4 and Fig. 1). The indel TCT in
intron 4 (rs1157899) was significantly associated, in vari-
ant homozygotes only, with higher free T. A similar asso-
ciation was observed with the GG form of the T3G SNP
(rs727479) in intron 2; the LD between the SNP and indel
was 0.93. Figure 1 shows the association of theCYP19A1
polymorphisms with circulating E2 levels. The 3-UTR
T3 C SNP (rs10046), intron 4 TCT indel (rs11575899),
and two intron 2 SNPs (rs2414096 and rs727479) were
TABLE 3. Influence of AR, ESR, and LHB polymorphisms on sex hormones
Gene Polymorphism Sex hormone Genotype n (%) Mean valuesa (95% CI) P value
ARb rs6152 Total E2 (pmol/liter) GG 2189 (83.1) 72.46 (69.91, 75.02)
AA 446 (16.9) 67.78 (64.52, 71.04) 2.32  104
Free E2 (pmol/liter) GG 2189 (83.1) 1.26 (1.22, 1.31)
AA 446 (16.9) 1.17 (1.11, 1.22) 1.96  105
Bioavailable E2 (pmol/liter) GG 2189 (83.1) 51.01 (49.21, 52.81)
AA 446 (16.9) 47.31 (45.02, 49.59) 2.53  105
ESR2 rs1256031 E2/T ratio TT 790 (28.9) 4.65 (4.44, 4.87)
TC 1366 (50.0) 4.56 (4.37, 4.75) 3.78  101
CC 577 (21.1) 4.29 (4.06, 4.53) 5.52  103
LHB rs2013040 Free E2 (pmol/liter) CC 2319 (91.4) 1.23 (1.18, 1.28)
CT 217 (8.6) 1.32 (1.24, 1.39) 4.23  103
Bioavailable E2 (pmol/liter) CC 2319 (91.4) 49.80 (47.96, 51.64)
CT 217 (8.6) 53.14 (50.29, 56.00) 5.44  103
E2/T ratio CC 2319 (91.4) 4.51 (4.33, 4.68)
CT 217 (8.6) 4.99 (4.64, 5.34) 3.65  103
V-LHB LH (nmol/liter) / 2574 (83.7) 6.48 (6.04, 6.91)
/ and / 500 (16.3) 5.94 (5.41, 6.48) 7.55  103
LHCGR rs6545061 E2/T ratio CC 694 (25.8) 4.66 (4.44, 4.89)
CT 1357 (50.3) 4.52 (4.34, 4.71) 2.03  101
TT 645 (23.9) 4.29 (4.06, 4.52) 4.22  103
a Adjusted mean value for a man aged 60 from center 1 (Florence).
b Results were very similar for all AR SNPs, so only rs6152 is presented because they are in very strong LD (r2  0.097) for all pair-wise
comparisons.
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associated with lower E2. Associations with higher serum
E2 were observed with three SNPs present in intron 1
(rs10519299, rs12050767, and rs749292). The minor al-
leles of these three SNPsare in strongLDwith the common
alleles of the other associated SNPs in the block (rs10046
and rs2414096) and therefore represent the same effect.
Associations were also observed betweenCYP19A1 poly-
morphisms and measures of insulin resistance (Table 4).
Strongest was the association between the 3-UTR T3C
SNP (rs10046) and higher levels of HOMA-IR. No asso-
ciations (i.e. P0.01)were observedwith anyof the other
nonhormonal phenotypes. None of these associations dif-
fered by center.
Additional data are presented on associations with the
hormonal (Supplemental Table 2) or phenotypic (Supple-
mental Table 3) parameters at borderline level of signifi-
cance (0.01  P  0.05). There was no evidence of any
epistatic effects between genes associated with hormonal
parameters.
Discussion
In this large population-based study of middle-aged and
elderly European men, we found significant associations
between genes related to pituitary-testicular endocrine
function and circulating reproductive hormone levels
measured using state of the art gas chromatography-mass
spectrometry techniques. The availability of extensive
clinical and laboratory measurements gave us the oppor-
tunity to look for detailed and robust genotypic/pheno-
typic correlations.
Relatively little is known about the influence of genetic
polymorphisms on function of the hypothalamic-pitu-
itary-testicular axis. Twin studies have demonstrated that
genetic factors account for more than 50% of the vari-
ability on male serum gonadotropin, sex steroid, and
SHBG levels (25, 26).With respect to individual genes, the
most extensively studied single genetic variant is the AR
exon 1 CAG repeat (23, 27). Only minor effects of this
polymorphismon circulatingTandE2 levels are apparent,
reaching statistical significance with large sample sizes.
We have reported previously from the EMAS cohort as-
sociations of the AR exon 1 CAG repeat polymorphism
with endocrine andmetabolic parameters (23), and ofAR
exon 1 CAG repeat and other polymorphisms with heel
ultrasound parameters (8). Other genes with polymor-
phisms associatedwith androgen and/or estrogen levels in
men include SHBG (28), CYP17 (29), CYP19A1 (30),
17HSD5 (31), anduridinediphosphate glucuronyltrans-
ferase 2B7 (UGT2B7) (32), but many potentially impor-
tant polymorphic influences have apparently not yet been
identified.
The polymorphisms genotyped in SHBG had multiple
effects. Besides the cognate protein, circulating levels of
LH, total and free T, total E2, and the LH  T product
were affected. The Asp356Asn (GAC3 AAC) mutation
TABLE 4. Influence of CYP19A1 polymorphisms on sex hormones and related phenotypes
Polymorphism Genotype n (%) Mean valuesa (95% CI) P value
Sex hormones
Free T (pmol/liter) rs11575899b TCT/TCT 1215 (44.6) 298.55 (290.06, 307.03)
TCT/ 1191 (43.7) 297.82 (289.65, 305.99) 8.12  101
/ 317 (11.7) 313.42 (302.56, 324.28) 2.10  103
rs727479b TT 1225 (46.9) 298.09 (289.53, 306.65)
TG 1093 (41.9) 296.10 (287.62, 304.58) 5.33  101
Related phenotypes
HOMA-IR rs2414096 AA 704 (26.8) 2.50 (2.20, 2.80)
AG 1284 (48.9) 2.92 (2.68, 3.15) 2.64  103
GG 638 (24.3) 2.83 (2.55, 3.10) 3.93  102
rs11575899b TCT/TCT 1215 (44.6) 2.63 (2.38, 2.89)
TCT/ 1191 (43.7) 2.95 (2.71, 3.18) 8.33  103
/ 317 (11.7) 2.84 (2.49, 3.20) 2.40  101
rs10046 TT 764 (28.2) 2.53 (2.24, 2.81)
TC 1358 (50.2) 2.87 (2.63, 3.10) 9.36  103
CC 583 (21.6) 2.97 (2.68, 3.25) 4.98  103
HOMA-S rs2414096b AA 704 (26.8) 0.57 (0.52, 0.61)
AG 1284 (48.9) 0.52 (0.48, 0.56) 6.50  103
GG 638 (24.3) 0.54 (0.49, 0.58) 1.10  101
QUICKI rs2414096b AA 704 (26.8) 0.266 (0.260, 0.272)
AG 1284 (48.9) 0.259 (0.254, 0.264) 3.26  103
GG 638 (24.3) 0.261 (0.256, 0.267) 7.49  102
a Adjusted mean value for a man aged 60 from center 1 (Florence).
b Significant association with homo- or heterozygotes only.
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in exon 8 of SHBG (rs6259) induces an additional con-
sensus site for N-glycosylation, increasing circulatory
half-life of the variant SHBG protein without affecting its
steroid-binding affinity (33) or steady-state plasma levels
(34), which our findings confirmed. Variable associations
of this polymorphism, depending on age of men, were
recently reported between SHBG and T levels (35). The
only significant association we found with this polymor-
phismwas the slightly but significantly (P0.01) elevated
level of freeT inheterozygotes. Theother two SHBGpoly-
morphisms, a TAAAA repeat in the promoter region and
G3A transversion in intron 1 (rs1799941), had high LD
(r2  0.89) as previously shown (36), with consequent
similar correlations with hormone levels. Short repeats,
i.e. (TAAAA)6,were associatedwithhigher serum levels of
SHBG, total T and E2, and higher LH  T product. In
addition, higher LH levels were associated with AA geno-
type of the rs1799941 polymorphism. Higher SHBG lev-
els are thus associated with the expected higher total, but
not free, T and E2 levels. Although in vitro studies have
shown that the (TAAAA)6 allele reduces SHBG gene ex-
pression (22), opposite in vivo findings in men are con-
sistent. Our findings confirm the three previous findings
onhigher SHBG levels in associationwith shorterTAAAA
repeats (28, 34, 35), but not a very recent finding on their
association with rs6259 (37).
The association of the two CYP19A1 polymorphisms
(rs11575899 and rs727479) with lower E2 levels and el-
evated levels of free and bioavailable T matches well be-
cause the potent negative feedback action of E2 on LH
secretion should be suppressed, resulting in elevated T
level (38).However,we did not find increased LH levels in
men with these SNPs, probably due to insufficient effect
size and/or high variability in levels of this hormone. We
have reported previously in the EMAS cohortmoderate to
strong associations between CYP19A1 polymorphisms
and bone ultrasound density in a LD block spanning from
intron 1 to the 3-UTR (8). Our current finding that the
same polymorphisms (rs10519299, 12050767, and
749292) are alsopositively associatedwith serumE2 levels
agrees with a very recent study showing similar associa-
tion with higher E2 levels and lumbar spine BMD (30).
These studies strengthen the contention that genetic vari-
ability inCYP19A1 significantly affects circulating E2 lev-
els and consequent BMD. Two SNPs in ESR1were found
inour previous study to affect BMD,but not circulatingE2
levels (8). In the current study, only one ESR2 polymor-
phism had amild effect on the LHTproduct. Hence, on
the basis of this limited analysis, the genetic variability of
aromatase has greater influence on circulating sex hor-
mone levels than that of estrogen receptors.
The common V-LH (Trp8Arg/Ile15Thr) differs func-
tionally fromWT-LH,predisposing its carriers tomild but
significant alterations in reproductive function, such as
subfertility, polycystic ovary syndrome, and delayed
tempo of puberty (9). In a group of independently living
elderly men, a significant positive correlation between fat
mass and serum leptin levelwasonly observed inheterozy-
gous carriers of V-LHB (39). The variant allele is tran-
scriptionallymore active thanWT-LHB due to additional
differences in its promoter sequence, and there are qual-
itative andquantitative differences inLHaction in carriers
ofV-LHB (9). The significantly lower LH level in carriers
FIG. 1. Influence of CYP19A1 polymorphisms on serum total E2.
-Coefficients and 95% CI for mean difference in total E2 (pmol/liter)
for heterozygotes () and variant homozygotes (f) compared with
common homozygotes. Position of SNPs within the gene and pairwise
LD comparisons are also shown. The LD plot shows D values (no
number where D  1, no evidence of recombination) and is colored
by r2 [correlation coefficient between SNPs, black  1 (SNPs predict
one another completely), white  0, gray  intermediate]. The
associated SNPs lie within a block of high LD.
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ofV-LHB agrees with the previously documented shorter
circulatory half-life of V-LH (9). The other LHB poly-
morphism, a C 3 T change in the 3-UTR, in heterozy-
gotes showed a borderline correlation with higher total
and free E2 levels. Due to the low MAF (0.04), these
findings must be interpreted with caution. Several poly-
morphisms have also been described in LHCGR (24).
We determined five of these, but only one, rs654061 in
intron 4, showed association with lowered E2/T ratio in
homozygotes.
Besides the widely studied AR CAG repeat in exon 1
there are multiple SNPs in this gene (27). After our pre-
vious report on significant association of the CAG repeat
lengthwith serumTandE2 levels in theEMAScohort (23),
we nowgenotyped five SNPs (one in exon 1, four in intron
1). Because of high LD, the phenotypic correlation was
similar in all five SNPs, i.e. a negative association with
circulating E2 (total, free, bioavailable). Intriguingly, the
major allele of rs6152 (G), associated with higher E2 lev-
els, is strongly associated with male-pattern baldness (40)
and higher-grade prostate cancer (41). Although the con-
nection of the latter associations with altered circulating
estrogen levels is hypothetical, altered estrogen/androgen
ratio may be involved.
Polymorphisms in SRD5A2 have been associated with
riskofprostate cancer,but thebiochemical evidence for their
relationship with androgen levels is controversial (42). Un-
like some findings on effects of the V89L polymorphism
(rs523349) (43, 44) we could not confirm associations with
serum androgen levels. Instead, the intron 3 C 3 A SNP
(rs7571644) and the long form of the TA repeat polymor-
phism in 3-UTR (0/0 vs. 9/9) were weakly but significantly
(P0.01) associatedwith increased levels of bioavailableT.
It is apparent that SRD5A2 polymorphisms are not a major
determinant of circulating T and E2 levels.
In this analysis, we did not exclude subjects who were
taking medications that affect hormone levels. However,
when we subsequently tested the effect of such exclusion,
it made no difference to the results. Given that this study
recruited subjects from eight European countries, one
might expect some variation between the different popu-
lations. Indeed, there were some statistically significant
differences in both allele frequencies and hormones be-
tween some study centers. In the analysis, we included the
data from all centers in the regression models and calcu-
lated corrected SE values to account for any center differ-
ences. We then fitted interaction terms to the models to
further explore the influence of center. The associations
observed were the same in all centers, apart from the as-
sociation between the polymorphism in intron 1 of SHBG
(rs1799941) and LH  T product, which differed very
modestly (P  0.048) in Florence, Santiago, and Tartu
compared with the other five centers.
In conclusion, we found several associations of genetic
polymorphisms in genes related to sex hormone produc-
tion with parameters of hormonal balance of men, but
only mild effects were observed at the secondary pheno-
typic level. Although the variability of sex hormone and
SHBG levels is under stronggenetic influence, the complex
interactions between multiple genes and environment ap-
parently dilute these responses to the extent that only a few
of them are discernible at the phenotypic level.
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